Journal
PARKINSONISM & RELATED DISORDERS
Volume 47, Issue -, Pages 3-7Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2017.12.006
Keywords
Parkinson's disease; Mild cognitive impairment; Dementia; Neuropsychology
Categories
Funding
- NIMH [MH19535]
- Michael J. Fox Foundation for Parkinson's Research
- AbbVie Radiopharmaceutical
- Avid Radiopharmaceutical
- Biogen Idec
- Bio-Legend
- Bristol-Meyers Squibb
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Eli Lilly and Company
- Lundbeck
- Merck
- Meso Scale Discovery
- Pfizer Inc.
- Piramal Imaging
- Roche group
- Sanofi-Genzyme
- Servier
- Takeda
- TEVA
- UCB
Ask authors/readers for more resources
Introduction: Past studies have shown that a large portion of individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI) will revert to a cognitively intact (CI) status in the future. Aging studies have shown that individuals who revert from MCI to CI are at increased risk for reconverting to MCI or dementia in the future. The current study examined if individuals who revert from PD-mild cognitive impairment (PD-MCI) to CI will be at increased risk for future PD-MCI and Parkinson's disease dementia (PDD). Method: The study utilized data from the Parkinson's Progression Markers Initiative (PPMI). The sample included 364 newly diagnosed PD participants who were followed annually for up to 4 years. Based on the first and second assessments, we identified individuals who were CI at each assessment (CI-Stable) and individuals who were PD-MCI at baseline but then reverted to CI (Reversion). Analyses examined if participants in the Reversion group were at greater risk, relative to the CI-Stable group, for cognitive impairment at future assessments. Results: Participants in the Reversion group were at greater risk for future cognitive impairment (PD-MCI or PDD) at the 2nd, 3rd and 4th annual follow-up, relative to the CI-Stable group. The Reversion group continued to be at increased risk for future cognitive impairment when adjusting for age, gender, education, depressive symptoms, and motor severity. Conclusion: A large proportion of individuals with PD-MCI will not show evidence of cognitive impairment within a year. However, these reverters continue to be at risk for future development of cognitive impairment. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available